When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Lenacapavir - Wikipedia

    en.wikipedia.org/wiki/Lenacapavir

    Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]

  3. List of antiretroviral fixed-dose combinations - Wikipedia

    en.wikipedia.org/wiki/List_of_antiretroviral...

    Food and Drug Administration (FDA) approval date: European Medicines Agency (EMA) approval date: Health Canada approval date: Company: Single-tablet regimen? NRTIs / NtRTIs: NNRTI: INSTI: PI: PK enhancer: Combivir: lamivudine zidovudine: September 26, 1997 ViiV Healthcare: No Kaletra (developed countries) Aluvia (developing countries) lopinavir ...

  4. Lenacapavir injection lowers HIV risk by 96% - AOL

    www.aol.com/lenacapavir-injection-lowers-hiv...

    Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown. ... Researchers note that current approval of ...

  5. PDUFA date - Wikipedia

    en.wikipedia.org/wiki/PDUFA_date

    The PDUFA date thus serves as a 'best estimate' of when a decision on a New Drug Application or a Biologics License Application would be forthcoming. This response may be a decision to approve the application or a Complete Response Letter (CRL). The PDUFA date may be extended by the Food and Drug Administration in certain circumstances. [6]

  6. An injectable HIV-prevention drug is highly effective — but ...

    www.aol.com/news/injectable-hiv-prevention-drug...

    Gilead plans to submit lenacapavir for approval for use as PrEP to the Food and Drug Administration by the end of the year. So this powerful new HIV-prevention tool could hit the U.S. market by ...

  7. U.S. FDA approves Gilead's long-acting HIV drug Sunlenca - AOL

    www.aol.com/lifestyle/u-fda-approves-gileads...

    Gilead's Sunlenca, whose common name is lenacapavir, is given once every six months as an injection, but will be in addition to the current treatment regimen of patients. ... U.S. FDA approves ...

  8. HIV capsid inhibition - Wikipedia

    en.wikipedia.org/wiki/HIV_capsid_inhibition

    The binding pocket for Lenacapavir was first described in 2009, with the small molecule PF-3450074 (PF74) developed by Pfizer. [15] PF74 was not developed clinically due to its fast metabolic breakdown and poor bioavailability , but its binding pocket has been well characterized and frequently targeted.

  9. Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

    www.aol.com/news/gileads-gild-biktarvy-gets-fda...

    For premium support please call: 800-290-4726 more ways to reach us